NexGel Inc (NXGL)
2.22
-0.01
(-0.45%)
USD |
NASDAQ |
May 03, 16:00
NexGel Research and Development Expense (Quarterly): 0.013M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.013M |
| September 30, 2023 | 0.006M |
| June 30, 2023 | 0.055M |
| March 31, 2023 | 0.029M |
| December 31, 2022 | 0.039M |
| September 30, 2022 | 0.193M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.111M |
| March 31, 2022 | 0.024M |
| December 31, 2021 | 0.014M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.01M |
| March 31, 2021 | 0.007M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2021
0.193M
Maximum
Sep 2022
0.0418M
Average
0.019M
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics Inc | 7.585M |
| The Cooper Companies Inc | 39.50M |
| Staar Surgical Co | 10.87M |
| OrthoPediatrics Corp | 2.747M |
| Innovative Eyewear Inc | 0.1208M |